Experimental gene therapy targets common cancer protein
NCT ID NCT05035407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new type of immunotherapy for people with advanced cancers that carry a specific protein called KK-LC-1. The treatment involved collecting a patient's own immune cells, modifying them in the lab to better recognize and attack cancer cells, and infusing them back along with a drug to help them survive. The study aimed to find a safe dose and was open to adults with gastric, breast, cervical, lung, or other epithelial cancers that tested positive for KK-LC-1.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KK-LC-1 T cell receptor (TCR) gene therapy plus aldesleukin (IL-2)
- What this could lead to
- If successful, this could point toward a new treatment option for several hard-to-treat cancers that express the KK-LC-1 protein.
- What could go wrong
- This is an early phase 1 trial focused on safety, not effectiveness. The trial was terminated, so results may be limited. Side effects from chemotherapy, cell infusion, and aldesleukin can be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KITA-KYUSHU LUNG CANCER ANTIGEN 1, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States